1. Home
  2. SNT vs IMMP Comparison

SNT vs IMMP Comparison

Compare SNT & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Senstar Technologies Ltd.

SNT

Senstar Technologies Ltd.

HOLD

Current Price

$1.83

Market Cap

64.6M

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$0.39

Market Cap

61.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNT
IMMP
Founded
1965
1987
Country
Canada
Australia
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
64.6M
61.4M
IPO Year
2023
2012

Fundamental Metrics

Financial Performance
Metric
SNT
IMMP
Price
$1.83
$0.39
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$5.50
AVG Volume (30 Days)
23.0K
389.2K
Earning Date
04-23-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$445.09
Revenue Next Year
N/A
N/A
P/E Ratio
$19.22
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.60
$0.29
52 Week High
$5.34
$3.53

Technical Indicators

Market Signals
Indicator
SNT
IMMP
Relative Strength Index (RSI) 34.85 42.43
Support Level $1.71 $0.35
Resistance Level $2.87 $0.46
Average True Range (ATR) 0.14 0.02
MACD 0.02 -0.00
Stochastic Oscillator 40.01 16.08

Price Performance

Historical Comparison
SNT
IMMP

About SNT Senstar Technologies Ltd.

Senstar Technologies Corp is an international provider of comprehensive physical, video, and access control security products and solutions. The company offers comprehensive solutions for critical sites, which leverage its broad portfolio of homegrown PIDS (Perimeter Intrusion Detection Systems), advanced VMS and SMS (Video Management Software and Security Management Software) with native IVA (Intelligent Video Analytics) security solutions, as well as access control products and technologies. Geographically, the company operates in North America, which derives maximum revenue; Europe; APAC; South and Latin America; and Others.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: